Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing proprietary drug delivery formulations for rare and orphan diseases. The company is advancing a small pipeline of drug candidates, with GTx-104 as its lead program, and has not yet generated product revenue.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaClinical-stage product candidates being developed for rare and orphan disease indications.
Proprietary formulations designed to improve efficacy, onset, tolerability, and compliance of existing compounds.
Internal R&D, clinical development, and FDA submission work supporting pipeline advancement.
Potential post-approval sales, marketing, and distribution of approved drug products.
Asiakkaat
The company does not yet sell commercial products, so its near-term 'customers' are primarily regulators, clinical investigators, CROs, CMOs, and potential future licensing or commercialization partners. If approved, its end customers would be physicians, pharmacists, hospitals, and patients treating rare and orphan diseases, with reimbursement decisions also influencing adoption.
FDA, CROs, and CMOs that support clinical testing, manufacturing, and approval pathways for the pipeline.
Specialists and care settings that would use approved products for rare and orphan disease treatment.
Medicaid, Medicare Part B, 340B entities, and other payors that affect pricing and access after approval.
Potential commercialization partners for larger-market products such as GTx-101.
Strategia
The company’s strategy is to advance its rare-disease pipeline, complete development for GTx-104, and pursue FDA approval while preserving optionality for GTx-102 and GTx-101. Because it has no product revenue, the near-term strategic priority is financing the business through equity, debt, or non-dilutive collaborations until a commercial asset is approved.
This is the lead asset and the most direct path to first commercial revenue.
The company expects continued operating losses and needs capital before cash runs out.
Approval alone is not enough; the company needs sales, marketing, and distribution capability.
Maantiede
Grace Therapeutics is headquartered and operationally concentrated in the United States, where all six full-time employees were located as of March 31, 2025. Its current development, regulatory, and potential commercialization activities are U.S.-centric, although its intellectual property portfolio spans multiple jurisdictions worldwide.
Riskit
Grace Therapeutics is exposed to classic clinical-stage biotech risks: trial failure, regulatory delay, financing risk, and uncertainty around eventual market acceptance. It also faces manufacturing, intellectual property, and reimbursement risks that can materially affect whether any approved product can be produced, protected, and sold profitably.
- Clinical development failure or delayVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company depends on successful trials and FDA approval to create any product revenue.
Kohdistuu - Financing and liquidity shortfallVaikutus: KriittinenTodennäköisyys: Kohtalainen
Management expects to need additional capital before current resources are exhausted.
Kohdistuu: Operating runway into third calendar quarter of 2026
- Manufacturing and supply chain disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Clinical and future commercial supply depend on third-party CMOs meeting cGMP and quality requirements.
Kohdistuu: Clinical materials and scale-up
- Intellectual property challengesVaikutus: KorkeaTodennäköisyys: Kohtalainen
Third-party patent claims or weak protection could limit commercialization or increase costs.
Kohdistuu: Drug delivery technologies and pipeline candidates
- Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Medicaid, Medicare Part B, and 340B rules can reduce realized pricing after approval.
Kohdistuu: U.S. commercial launch
Kirjanpito
Harkinnanvaraiset erätClinical trial and CMO/CRO costs are estimated based on work performed and invoices received.
Vaikutus: Can shift quarterly R&D expense and liabilities
Fair value remeasurement can create large non-cash gains or losses.
Vaikutus: Can materially affect net income/loss
Acquired IPR&D is capitalized and may be written off if programs fail or are discontinued.
Vaikutus: Could cause large impairment charges
Equity awards are a meaningful part of compensation for a small biotech workforce.
Vaikutus: Raises operating expenses and affects per-share results
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Werewolf Therapeutics, Inc.
HOWL · Pharmaceutical Preparations
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Päivitetty: 24.9.2026